Shots: The approval is based on P-III AWARD-11 study assessing Trulicity (3.0mg & 4.5mg, qw) vs Trulicity (1.5 mg) in 1,842 patients with T2D The P-III study demonstrated that additional […]readmore
Tags : Trulicity
Shots: The approval follows the REWIND study which involves assessing of Trulicity + SoC (1.5mg) vs PBO + SoC in adults with T2D The study showed reduction in MACE events […]readmore
Shots: The EMA’s CHMP recommends an update to the Trulicity label and indication statement to include results from REWIND CV outcome study, demonstrating 12% reduction in MACE, reflecting both glycemic […]readmore
Shots: The P-III AWARD-11 study results involve assessing of Trulicity (3.0mg/4.5mg, qw) vs Trulicity (1.5mg, qw) in 1842 patients with type 2 diabetes for 52wks. The P-III AWARD study resulted […]readmore